267 related articles for article (PubMed ID: 35857294)
21. Downstaging Outcomes for Hepatocellular Carcinoma: Results From the Multicenter Evaluation of Reduction in Tumor Size before Liver Transplantation (MERITS-LT) Consortium.
Mehta N; Frenette C; Tabrizian P; Hoteit M; Guy J; Parikh N; Ghaziani TT; Dhanasekaran R; Dodge JL; Natarajan B; Holzner ML; Frankul L; Chan W; Fobar A; Florman S; Yao FY
Gastroenterology; 2021 Nov; 161(5):1502-1512. PubMed ID: 34331914
[TBL] [Abstract][Full Text] [Related]
22. International study on the outcome of locoregional therapy for liver transplant in hepatocellular carcinoma beyond Milan criteria.
Degroote H; Piñero F; Costentin C; Notarpaolo A; Boin IF; Boudjema K; Baccaro C; Chagas AL; Bachellier P; Ettorre GM; Poniachik J; Muscari F; Di Benedetto F; Duque SH; Salame E; Cillo U; Gadano A; Vanlemmens C; Fagiuoli S; Rubinstein F; Burra P; Cherqui D; Silva M; Van Vlierberghe H; Duvoux C;
JHEP Rep; 2021 Oct; 3(5):100331. PubMed ID: 34485882
[TBL] [Abstract][Full Text] [Related]
23. Development and validation of a REcurrent Liver cAncer Prediction ScorE (RELAPSE) following liver transplantation in patients with hepatocellular carcinoma: Analysis of the US Multicenter HCC Transplant Consortium.
Tran BV; Moris D; Markovic D; Zaribafzadeh H; Henao R; Lai Q; Florman SS; Tabrizian P; Haydel B; Ruiz RM; Klintmalm GB; Lee DD; Taner CB; Hoteit M; Levine MH; Cillo U; Vitale A; Verna EC; Halazun KJ; Tevar AD; Humar A; Chapman WC; Vachharajani N; Aucejo F; Lerut J; Ciccarelli O; Nguyen MH; Melcher ML; Viveiros A; Schaefer B; Hoppe-Lotichius M; Mittler J; Nydam TL; Markmann JF; Rossi M; Mobley C; Ghobrial M; Langnas AN; Carney CA; Berumen J; Schnickel GT; Sudan DL; Hong JC; Rana A; Jones CM; Fishbein TM; Busuttil RW; Barbas AS; Agopian VG
Liver Transpl; 2023 Jul; 29(7):683-697. PubMed ID: 37029083
[TBL] [Abstract][Full Text] [Related]
24. Alpha-Fetoprotein Slope >7.5 ng/mL per Month Predicts Microvascular Invasion and Tumor Recurrence After Liver Transplantation for Hepatocellular Carcinoma.
Giard JM; Mehta N; Dodge JL; Roberts JP; Yao FY
Transplantation; 2018 May; 102(5):816-822. PubMed ID: 29505494
[TBL] [Abstract][Full Text] [Related]
25. Benefit of Treating Hepatocellular Carcinoma Recurrence after Liver Transplantation and Analysis of Prognostic Factors for Survival in a Large Euro-American Series.
Sapisochin G; Goldaracena N; Astete S; Laurence JM; Davidson D; Rafael E; Castells L; Sandroussi C; Bilbao I; Dopazo C; Grant DR; Lázaro JL; Caralt M; Ghanekar A; McGilvray ID; Lilly L; Cattral MS; Selzner M; Charco R; Greig PD
Ann Surg Oncol; 2015 Jul; 22(7):2286-94. PubMed ID: 25472651
[TBL] [Abstract][Full Text] [Related]
26. Alpha-fetoprotein level > 1000 ng/mL as an exclusion criterion for liver transplantation in patients with hepatocellular carcinoma meeting the Milan criteria.
Hameed B; Mehta N; Sapisochin G; Roberts JP; Yao FY
Liver Transpl; 2014 Aug; 20(8):945-51. PubMed ID: 24797281
[TBL] [Abstract][Full Text] [Related]
27. Hepatocellular carcinoma downstaging in liver transplantation.
Yu CY; Ou HY; Huang TL; Chen TY; Tsang LL; Chen CL; Cheng YF
Transplant Proc; 2012 Mar; 44(2):412-4. PubMed ID: 22410030
[TBL] [Abstract][Full Text] [Related]
28. Rate of tumor growth predicts recurrence of hepatocellular carcinoma after liver transplantation in patients beyond Milan or UCSF criteria.
Hanouneh IA; Macaron C; Lopez R; Aucejo F; Zein NN
Transplant Proc; 2011 Dec; 43(10):3813-8. PubMed ID: 22172852
[TBL] [Abstract][Full Text] [Related]
29. Downstaging hepatocellular carcinoma: A systematic review and pooled analysis.
Parikh ND; Waljee AK; Singal AG
Liver Transpl; 2015 Sep; 21(9):1142-52. PubMed ID: 25981135
[TBL] [Abstract][Full Text] [Related]
30. Validation of the AFP model as a predictor of HCC recurrence in patients with viral hepatitis-related cirrhosis who had received a liver transplant for HCC.
Notarpaolo A; Layese R; Magistri P; Gambato M; Colledan M; Magini G; Miglioresi L; Vitale A; Vennarecci G; Ambrosio CD; Burra P; Di Benedetto F; Fagiuoli S; Colasanti M; Maria Ettorre G; Andreoli A; Cillo U; Laurent A; Katsahian S; Audureau E; Roudot-Thoraval F; Duvoux C
J Hepatol; 2017 Mar; 66(3):552-559. PubMed ID: 27899297
[TBL] [Abstract][Full Text] [Related]
31. Identifying patients at higher risk of hepatocellular carcinoma recurrence after liver transplantation in a multicenter cohort study from Argentina.
Piñero F; Marciano S; Anders M; Orozco Ganem F; Zerega A; Cagliani J; Andriani O; de Santibañes E; Gil O; Podestá LG; McCormack L; Gadano A; Silva M
Eur J Gastroenterol Hepatol; 2016 Apr; 28(4):421-7. PubMed ID: 26684693
[TBL] [Abstract][Full Text] [Related]
32. Downstaging of hepatocellular cancer before liver transplant: long-term outcome compared to tumors within Milan criteria.
Yao FY; Mehta N; Flemming J; Dodge J; Hameed B; Fix O; Hirose R; Fidelman N; Kerlan RK; Roberts JP
Hepatology; 2015 Jun; 61(6):1968-77. PubMed ID: 25689978
[TBL] [Abstract][Full Text] [Related]
33. Hepatocellular carcinoma recurrence among liver transplant recipients within the Milan criteria.
Felga G; Evangelista AS; Salvalaggio PR; Curvelo LA; Della Guardia B; Almeida MD; Afonso RC; Ferraz-Neto BH
Transplant Proc; 2012 Oct; 44(8):2459-61. PubMed ID: 23026620
[TBL] [Abstract][Full Text] [Related]
34. Patient Selection for Downstaging of Hepatocellular Carcinoma Prior to Liver Transplantation-Adjusting the Odds?
Seehofer D; Petrowsky H; Schneeberger S; Vibert E; Ricke J; Sapisochin G; Nault JC; Berg T
Transpl Int; 2022; 35():10333. PubMed ID: 35529597
[No Abstract] [Full Text] [Related]
35. Excessive intraoperative blood loss independently predicts recurrence of hepatocellular carcinoma after liver transplantation.
Liu B; Teng F; Fu H; Guo WY; Shi XM; Ni ZJ; Gao XG; Ma J; Fu ZR; Ding GS
BMC Gastroenterol; 2015 Oct; 15():138. PubMed ID: 26472203
[TBL] [Abstract][Full Text] [Related]
36. A Simple Measure of Hepatocellular Carcinoma Burden Predicts Tumor Recurrence After Liver Transplantation: The Recurrent Hepatocellular Carcinoma-Initial, Maximum, Last Classification.
Vutien P; Dodge J; Bambha KM; Nordstrom EM; Gralla J; Campbell K; Levek C; Nydam T; Fix O; Ioannou G; Biggins SW
Liver Transpl; 2019 Apr; 25(4):559-570. PubMed ID: 30706653
[TBL] [Abstract][Full Text] [Related]
37. Serological Risk Index Based on Alpha-Fetoprotein and C-Reactive Protein to Indicate Futile Liver Transplantation Among Patients with Advanced Hepatocellular Carcinoma.
Kornberg A; Schernhammer M; Kornberg J; Friess H; Thrum K
Dig Dis Sci; 2019 Jan; 64(1):269-280. PubMed ID: 30259282
[TBL] [Abstract][Full Text] [Related]
38. Recurrence of hepatocellular carcinoma after liver transplantation: Is there a place for resection?
Fernandez-Sevilla E; Allard MA; Selten J; Golse N; Vibert E; Sa Cunha A; Cherqui D; Castaing D; Adam R
Liver Transpl; 2017 Apr; 23(4):440-447. PubMed ID: 28187493
[TBL] [Abstract][Full Text] [Related]
39. Predictive value of nodule size and differentiation in HCC recurrence after liver transplantation.
Guerrini GP; Pinelli D; Di Benedetto F; Marini E; Corno V; Guizzetti M; Aluffi A; Zambelli M; Fagiuoli S; Lucà MG; Lucianetti A; Colledan M
Surg Oncol; 2016 Dec; 25(4):419-428. PubMed ID: 26403621
[TBL] [Abstract][Full Text] [Related]
40. Alpha-fetoprotein and modified response evaluation criteria in solid tumors progression after locoregional therapy as predictors of hepatocellular cancer recurrence and death after transplantation.
Lai Q; Avolio AW; Graziadei I; Otto G; Rossi M; Tisone G; Goffette P; Vogel W; Pitton MB; Lerut J;
Liver Transpl; 2013 Oct; 19(10):1108-18. PubMed ID: 23873764
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
